CANTON, Mass., Dec. 1 /PRNewswire/ -- Organogenesis, Inc., a leading regenerative medicine company, has just been named the recipient of two prestigious awards honoring the company's cutting edge development, manufacturing and economic impact.
Organogenesis' manufacturing division has been named 2008 "Team of the Year" by Pharmaceutical Manufacturing, a prominent industry publication. The "Team of the Year" honor will be highlighted in the magazine's upcoming December 2008 issue. Additionally, the company was honored by the Massachusetts Alliance for Economic Development as the Silver winner of its Fifth Annual Team Massachusetts Economic Impact Award, presented at a November 25th awards event.
Organogenesis was the first company to successfully mass produce living regenerative medicine products -- reaching hundreds of thousands of patients in the U.S. and around the world. Its signature product, Apligraf(R), is the first living cell therapy to have received U.S. Food and Drug Administration (FDA) approvals to close both diabetic foot ulcers (DFUs) and venous leg ulcers (VLUs).
"We are honored to receive national and state recognition of the company's vision, its ingenuity and hard work," said Geoff MacKay, CEO of Organogenesis. "Organogenesis is committed to bringing the promise of regenerative medicine into everyday medical care. To have our efforts and hard work recognized in this way is very gratifying for the company and our employees."
MacKay continued, "The intricate processes required to mass produce a living cell therapy product require a great deal of innovation and dedication, and our top-notch manufacturing group hits its target every day. This team is in large part responsible for the quality, the growth and the contribution that marks Organogenesis as a regenerative medicine leader in Massachusetts and around the world."
Award Recognizes Manufacturing Excellence
Pharmaceutical Manufacturing, a national trade magazine, is honoring Organogenesis in the small manufacturer category. Pharmaceutical Manufacturing's annual award recognizes manufacturing teams in the life sciences industry that have undertaken sizable challenges, excelled in their work, improved facility morale and team spirit, and achieved measurable, meaningful results. A preview of the "Team of the Year" award article is available online at http://www.pharmamanufacturing.com/articles/2008/161.html.
According to the publication, "The Organogenesis Apligraf Manufacturing Team is responsible for growing Apligraf based upon a proprietary living cell technology with a very short shelf life that requires strict attention to detail and accurate production forecasting. These challenges have defined the manufacturing team. The team has a deep sense of fulfillment from making a meaningful product. Emblematic of its award-winning commitment, the team has firsthand knowledge of how patients benefit, and therefore a unique emotional connection to the product. The team translates this connection into manufacturing excellence."
Award Recognizes Massachusetts Economic Development Contributions
The Fifth Annual Team Massachusetts Economic Impact Award is the only award of its kind in the state, honoring a select group of companies from across the Commonwealth recognized for their outstanding contributions to the Massachusetts economy. Organogenesis is the Silver Medal recipient for 2008.
The Team Massachusetts Economic Impact Awards honor companies in all regions of the state that have expanded the number of jobs in Massachusetts and positively contributed to their surrounding communities. According to the organization, Organogenesis was selected because of its commitment to expanding both its headquarters and life sciences jobs within the state.
The Massachusetts Alliance for Economic Development is a private, non- profit partnership of business, industry leaders, and government dedicated to fostering economic growth in the Commonwealth.
About Regenerative Medicine
A new frontier in healthcare, regenerative medicine utilizes living human cells to repair or replace body tissue damaged by injury, disease or even the natural aging process.
Regenerative medicine is a multidisciplinary field which brings together biology, medicine, and engineering to empower scientists to grow living cells, tissues and organs in the laboratory, and to safely implant them into the human body for the purposes of healing.
Like human skin, Apligraf contains two layers of living cells: an outer (or epidermal) layer of protective skin cells, and an inner (or dermal) layer of cells. When placed on a wound previously unresponsive to treatment, Apligraf plays an active role by providing cells and proteins that help promote healing. In multiple controlled clinical studies, Apligraf has been shown to be an effective and safe wound care treatment, superior to conventional treatments. It has been used to treat many thousands of patients and is covered extensively by Medicare, Medicaid and by 350 private payers in the U.S.
About Organogenesis, Inc.
Having pioneered the field, Massachusetts based Organogenesis, Inc. is a world leading regenerative medicine company focused in the areas of bio-active wound healing, bio-surgery and oral regeneration. Organogenesis delivers living tissue "on demand," and its mission is to bring the medical marvel of regenerative medicine products to patients and to standardize their use in everyday medical care.
The company recently established European headquarters located in Switzerland, as well as announced an expansion of its U.S. headquarters. For more information, visit http://www.organogenesis.com.
|SOURCE Organogenesis, Inc.|
Copyright©2008 PR Newswire.
All rights reserved